Cancer Research

Corporate collaboration

Collaboration to discover novel targeted radioligand therapies

15 September 2023

Orano Med, a biotechnology company developing Lead-212 (212Pb) targeted alpha therapy against cancer, and Orbit Discovery, a company discovering therapeutic peptide hits, have entered into a collaboration to discover specific peptide receptor radionuclide therapies (PRRT) against cancer cells and advance the development of novel radiopharmaceuticals.   Under the terms of the agreement, Orbit will deploy […]

Cancer cells

Multi-platform collab to develop innovative oncology therapeutics 

14 September 2023

Moderna and Immatics have announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high, unmet medical need.   This broad multi-platform collaboration will leverage the scientific expertise and core operational capabilities of both companies, combining Immatics’ TCR platform with Moderna’s mRNA technology, and span various therapeutic modalities including […]

Bladder cancer

Janssen submits EMA filing for bladder cancer treatment 

14 September 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, with disease progression during or […]

CAR-T therapy

First base editing therapeutic for T-ALL/T-LL enters trials

8 September 2023

The first quadruplex-edited, allogeneic CAR-T cell therapy candidate has entered clinical trials in the US. The first patient has been treated with Beam Therapeutics’ BEAM-201 as part of a Phase I/II clinical study for the treatment of relapsed/refractory T-cell acute lymphoblastic leukaemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL). “As the first patient dosed with a Beam therapeutic candidate […]

Antibody drug conjugate

Antibody-drug conjugate extends overall survival in cervical cancer

7 September 2023

In the Phase III innovaTV 301 trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, Tivdak (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (OS). An independent data monitoring committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The key […]

Childhood Cancer Awareness Month

Five key studies into drugs for childhood cancers

7 September 2023

DDW’s Diana Spencer highlights five key clinical studies taking a new therapeutic approach to childhood cancers. Over 100 subtypes of childhood cancer exist today and it represents the most common cause of disease-related death in children. However, despite the fact that children’s response to adult cancer drugs is often poor, due to the challenges of […]

Telomeres on chromosomes

Study identifies potential new cancer drug targets

1 September 2023

A new study has provided insights into the biological mechanism that supports survival of hard-to-treat cancers. In the new study, led by scientists at The Institute of Cancer Research and published in Nature Communications, researchers identify a new cellular role of a protein called EXD2 nuclease and, importantly, its role in the so-called ALT (alternative […]

MRI of the brain showing glioblastoma

Plasmid DNA vaccine for brain cancer enters Phase I trial

30 August 2023

Immunomic Therapeutics has commenced its Phase I clinical trial evaluating ITI-1001, a plasmid DNA (pDNA) vaccine, for the treatment of Glioblastoma Multiforme (GBM), a rare but aggressive form of brain cancer. ITI-1001 is an investigational plasmid DNA vaccine therapy designed to target the pp65, IE-1 and gB viral antigens of Cytomegalovirus (CMV) which are expressed […]

""

CancerX initiative aims to boost innovation in cancer treatment

24 August 2023

The White House Cancer Moonshot initiative has announced a new public-private partnership to boost innovation in the fight against cancer. CancerX will be co-hosted by the Digital Medicine Society (DiMe) and Moffitt Cancer Center. It blends DiMe’s expertise in convening cross-disciplinary groups to develop clinical-quality resources on a tech timeline with Moffitt’s top research and […]

Medical laboratory

Phase Ib study proves efficacy of SFX-01 coated tablet formation

22 August 2023

Evgen Pharma has revealed the final data from its Phase Ib healthy volunteer study using the company’s new enteric coated tablet formation of its lead asset SFX-01. SFX-01 is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. The company has already completed three trials in patients, including a positive open label trial in metastatic breast […]

Breast cancer research

Where are the advances in treatments for triple-negative breast cancer?

21 August 2023

Diana Spencer investigates therapies in clinical development for triple-negative breast cancer and asks what future treatments might look like. Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases and is one of the main causes of death in women. However, because these cancers are not driven by any of the three […]

Cancer cell

Genetic biomarkers could personalise therapy for TNBC

16 August 2023

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The study, by researchers at The Institute of Cancer Research, London, shows that certain characteristics within patients’ primary tumours can predict how they will respond to different treatments […]

Tumour microenvironment

Immunotherapy for solid tumours progresses to human trials

14 August 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. Sosei Group and Cancer Research UK announced that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ immunotherapy drug HTL0039732. HTL0039732 works by blocking […]

Warfarin

Warfarin could be repurposed as a potent cancer drug

11 August 2023

A new study has shown that blood thinner warfarin could also treat cancer, as it stops tumours from interfering with a self-destruct mechanism that cells initiate when they detect mutations or other abnormalities (ferroptosis). The research by Columbia University researchers was conducted in human cells and in mice to uncover molecular processes that regulate ferroptosis. […]

""

Sitting down with… Neil Dhawan

10 August 2023

Reece Armstrong speaks to Neil Dhawan, the Co-founder and CEO of Totus Medicines about the company’s approach to drug discovery using fundamental technologies in chemistry, biology and artificial intelligence (AI). RA: How is Totus Medicines attempting to target untreatable or undruggable diseases? ND: Discovering a highly effective drug is like winning the lottery. If you […]

CAR-T therapy

Biologic CAR-T cell engager approved for UK clinical trial

9 August 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR-T cell therapy. The company’s collaboration partner, Cancer Research UK’s Centre for Drug Development, has sponsored and […]

« Previous
Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free